ClinicalTrials.gg

Program

parunoflast

A development code. Also written as “LY5625573”, “VTX3232 30 mg” and “VTX3232”.

Its studies are mostly in Obesity · Parkinson Disease, led by Eli Lilly.

Furthest: phase 2, since Aug 13, 20243 company-led studies, 1 open or runningNext primary completion: Jan 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly31 open or runningphase 2since Aug 13, 2024Aug 13, 2024Jan 2027phase 1 · NCT07867340
  • Named in Eli Lilly’s own pipeline as Parunoflast (VTX3232), phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 13, 2024First study: phase 2 study in Parkinson DiseaseFirst studyNCT06556173 · 11 enrolled · United States
  2. Jan 8, 2025Phase 2 study in ObesityNCT06771115 · 175 enrolled · United States
  3. Oct 5, 2026Phase 1 study in C-Reactive ProteinNCT07867340 · 96 planned · United States, Singapore

Ahead

  1. Jan 2027Primary completion: phase 1 study in C-Reactive ProteinNCT07867340

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07867340C-Reactive Protein · United States, Singapore1Not yet recruitingJan 202796
NCT06771115Obesity · United States2CompletedSep 10, 2025175
NCT06556173Parkinson Disease · United States2CompletedApr 4, 202511

How it is read

Names in the registry

  • “LY5625573”, 1 entry
  • “VTX3232 30 mg”, 1 entry
  • “VTX3232”, 1 entry

Codes read as this program: LY5625573, VTX3232.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.